vs
Side-by-side financial comparison of CF Industries (CF) and Hologic (HOLX). Click either name above to swap in a different company.
CF Industries is the larger business by last-quarter revenue ($1.9B vs $1.0B, roughly 1.8× Hologic). CF Industries runs the higher net margin — 26.4% vs 17.1%, a 9.3% gap on every dollar of revenue. On growth, CF Industries posted the faster year-over-year revenue change (22.8% vs 2.5%). CF Industries produced more free cash flow last quarter ($313.0M vs $215.2M). Over the past eight quarters, CF Industries's revenue compounded faster (12.8% CAGR vs 1.5%).
CF Industries Holdings, Inc. is an American manufacturer and distributor of agricultural fertilizers, including ammonia, urea, and ammonium nitrate products. The company is based in Northbrook, Illinois, a suburb of Chicago, and was founded in 1946 as the Central Farmers Fertilizer Company. For its first 56 years, it was a federation of regional agricultural supply cooperatives. CF then demutualized, and became a publicly traded company.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
CF vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $1.0B |
| Net Profit | $495.0M | $179.1M |
| Gross Margin | 40.9% | 56.0% |
| Operating Margin | 33.0% | 22.6% |
| Net Margin | 26.4% | 17.1% |
| Revenue YoY | 22.8% | 2.5% |
| Net Profit YoY | 26.3% | -10.9% |
| EPS (diluted) | $2.56 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9B | $1.0B | ||
| Q3 25 | $1.7B | $1.0B | ||
| Q2 25 | $1.9B | $1.0B | ||
| Q1 25 | $1.7B | $1.0B | ||
| Q4 24 | $1.5B | $1.0B | ||
| Q3 24 | $1.4B | $988.0M | ||
| Q2 24 | $1.6B | $1.0B | ||
| Q1 24 | $1.5B | $1.0B |
| Q4 25 | $495.0M | $179.1M | ||
| Q3 25 | $460.0M | $187.2M | ||
| Q2 25 | $492.0M | $194.9M | ||
| Q1 25 | $351.0M | $-17.4M | ||
| Q4 24 | $392.0M | $201.0M | ||
| Q3 24 | $341.0M | $178.6M | ||
| Q2 24 | $506.0M | $194.5M | ||
| Q1 24 | $238.0M | $169.9M |
| Q4 25 | 40.9% | 56.0% | ||
| Q3 25 | 38.1% | 55.6% | ||
| Q2 25 | 39.9% | 56.3% | ||
| Q1 25 | 34.4% | 37.5% | ||
| Q4 24 | 34.4% | 56.8% | ||
| Q3 24 | 32.4% | 56.4% | ||
| Q2 24 | 43.2% | 55.4% | ||
| Q1 24 | 27.8% | 53.3% |
| Q4 25 | 33.0% | 22.6% | ||
| Q3 25 | 35.0% | 22.6% | ||
| Q2 25 | 34.3% | 24.9% | ||
| Q1 25 | 27.4% | -0.7% | ||
| Q4 24 | 28.9% | 22.5% | ||
| Q3 24 | 26.6% | 23.3% | ||
| Q2 24 | 40.6% | 24.1% | ||
| Q1 24 | 20.6% | 20.7% |
| Q4 25 | 26.4% | 17.1% | ||
| Q3 25 | 27.7% | 17.8% | ||
| Q2 25 | 26.0% | 19.0% | ||
| Q1 25 | 21.1% | -1.7% | ||
| Q4 24 | 25.7% | 19.7% | ||
| Q3 24 | 24.9% | 18.1% | ||
| Q2 24 | 32.2% | 19.2% | ||
| Q1 24 | 16.2% | 16.7% |
| Q4 25 | $2.56 | $0.79 | ||
| Q3 25 | $2.19 | $0.84 | ||
| Q2 25 | $2.37 | $0.86 | ||
| Q1 25 | $1.85 | $-0.08 | ||
| Q4 24 | $1.86 | $0.87 | ||
| Q3 24 | $1.55 | $0.75 | ||
| Q2 24 | $2.30 | $0.82 | ||
| Q1 24 | $1.03 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.4B |
| Total DebtLower is stronger | $3.2B | $2.5B |
| Stockholders' EquityBook value | $4.8B | $5.2B |
| Total Assets | $14.1B | $9.2B |
| Debt / EquityLower = less leverage | 0.66× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | $3.2B | $2.5B | ||
| Q3 25 | $3.0B | $2.5B | ||
| Q2 25 | $3.0B | $2.5B | ||
| Q1 25 | $3.0B | $2.5B | ||
| Q4 24 | $3.0B | $2.5B | ||
| Q3 24 | $3.0B | $2.5B | ||
| Q2 24 | $3.0B | $2.5B | ||
| Q1 24 | $3.0B | $2.6B |
| Q4 25 | $4.8B | $5.2B | ||
| Q3 25 | $4.8B | $5.0B | ||
| Q2 25 | $5.0B | $4.8B | ||
| Q1 25 | $4.8B | $4.6B | ||
| Q4 24 | $5.0B | $4.8B | ||
| Q3 24 | $5.2B | $5.1B | ||
| Q2 24 | $5.5B | $5.0B | ||
| Q1 24 | $5.4B | $4.8B |
| Q4 25 | $14.1B | $9.2B | ||
| Q3 25 | $14.2B | $9.0B | ||
| Q2 25 | $13.8B | $8.8B | ||
| Q1 25 | $13.3B | $8.5B | ||
| Q4 24 | $13.5B | $8.7B | ||
| Q3 24 | $13.8B | $9.2B | ||
| Q2 24 | $13.8B | $8.9B | ||
| Q1 24 | $13.9B | $8.7B |
| Q4 25 | 0.66× | 0.48× | ||
| Q3 25 | 0.61× | 0.50× | ||
| Q2 25 | 0.60× | 0.52× | ||
| Q1 25 | 0.62× | 0.55× | ||
| Q4 24 | 0.60× | 0.53× | ||
| Q3 24 | 0.57× | 0.49× | ||
| Q2 24 | 0.54× | 0.51× | ||
| Q1 24 | 0.55× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $539.0M | $229.9M |
| Free Cash FlowOCF − Capex | $313.0M | $215.2M |
| FCF MarginFCF / Revenue | 16.7% | 20.5% |
| Capex IntensityCapex / Revenue | 12.1% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.09× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $1.8B | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $539.0M | $229.9M | ||
| Q3 25 | $1.1B | $355.1M | ||
| Q2 25 | $563.0M | $343.3M | ||
| Q1 25 | $586.0M | $169.4M | ||
| Q4 24 | $420.0M | $189.3M | ||
| Q3 24 | $931.0M | $367.0M | ||
| Q2 24 | $475.0M | $405.8M | ||
| Q1 24 | $445.0M | $292.4M |
| Q4 25 | $313.0M | $215.2M | ||
| Q3 25 | $717.0M | $341.4M | ||
| Q2 25 | $318.0M | $330.5M | ||
| Q1 25 | $454.0M | $153.9M | ||
| Q4 24 | $223.0M | $172.5M | ||
| Q3 24 | $792.0M | $350.6M | ||
| Q2 24 | $391.0M | $385.3M | ||
| Q1 24 | $347.0M | $279.6M |
| Q4 25 | 16.7% | 20.5% | ||
| Q3 25 | 43.2% | 32.5% | ||
| Q2 25 | 16.8% | 32.3% | ||
| Q1 25 | 27.3% | 15.3% | ||
| Q4 24 | 14.6% | 16.9% | ||
| Q3 24 | 57.8% | 35.5% | ||
| Q2 24 | 24.9% | 38.1% | ||
| Q1 24 | 23.6% | 27.5% |
| Q4 25 | 12.1% | 1.4% | ||
| Q3 25 | 20.9% | 1.3% | ||
| Q2 25 | 13.0% | 1.3% | ||
| Q1 25 | 7.9% | 1.5% | ||
| Q4 24 | 12.9% | 1.6% | ||
| Q3 24 | 10.1% | 1.7% | ||
| Q2 24 | 5.3% | 2.0% | ||
| Q1 24 | 6.7% | 1.3% |
| Q4 25 | 1.09× | 1.28× | ||
| Q3 25 | 2.31× | 1.90× | ||
| Q2 25 | 1.14× | 1.76× | ||
| Q1 25 | 1.67× | — | ||
| Q4 24 | 1.07× | 0.94× | ||
| Q3 24 | 2.73× | 2.05× | ||
| Q2 24 | 0.94× | 2.09× | ||
| Q1 24 | 1.87× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CF
| Ammonia | $591.0M | 32% |
| UAN | $493.0M | 26% |
| Urea | $372.0M | 20% |
| Other | $244.0M | 13% |
| Other Products | $147.0M | 8% |
| Ammonium Nitrate Segment | $25.0M | 1% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
